natgillin/translations-raw huggingface dataset:
In this study, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Procoralan compared with placebo (3.4% vs 2.9% yearly incidence rates). 
V tej študiji je pri posebni podskupini bolnikov s simptomatsko angino pektoris, zdravljenih z zdravilom Procoralan, prišlo do majhnega, vendar pomembnega povečanja združenega tveganja smrti zaradi srčno-žilne bolezni ali srčnega napada brez smrtnega izida v primerjavi s placebom (letni delež pogostnosti 3,4 % v primerjavi z 2,9 %).
A sixth study compared Procoralan with placebo in 19,102 patients with coronary artery disease and without clinical heart failure. 
V šesti študiji so primerjali zdravilo Procoralan in placebo pri 19 102 bolnikih z boleznijo koronarnih arterij brez kliničnega srčnega popuščanja.
Procoralan contains the active substance ivabradine. 
Zdravilo Procoralan vsebuje zdravilno učinkovino ivabradin.
What are the risks associated with Procoralan? 
Kakšna tveganja so povezana z zdravilom Procoralan?
Procoralan was compared with placebo (a dummy treatment) and other treatments in five main studies involving over 4,000 adults with long-term stable angina. 
Zdravilo Procoralan so primerjali s placebom (zdravilom brez zdravilne učinkovine) in drugimi zdravili v petih glavnih študijah, v katere je bilo vključenih več kot 4 000 odraslih s kronično stabilno angino pektoris.
Procoralan is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) who have a normal heart rhythm and whose heart rate is at least 75 beats per minute. 
Zdravilo Procoralan se uporablja tudi pri bolnikih s kroničnim srčnim popuščanjem (kadar srce ne more načrpati dovolj krvi po telesu), ki imajo sicer normalen srčni ritem, a je njihov srčni utrip najmanj 75 udarcev na minuto.
By lowering the heart rate, Procoralan reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms. 
Zdravilo Procoralan z zniževanjem srčnega utripa zmanjša obremenitev srca ter upočasni napredovanje srčnega popuščanja in ublaži simptome.
Procoralan was compared with placebo in one main study involving over 6,500 patients with long-term moderate to severe heart failure. 
Zdravilo Procoralan so primerjali s placebom v eni glavni študiji, v katero je bilo vključenih več kot 6 500 bolnikov s kroničnim zmernim do hudim srčnim popuščanjem.
Procoralan is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (disease of the heart caused by the obstruction of the blood vessels that supply blood to the heart muscle).The medicine is used in patients who have a normal heart rhythm, and whose heart rate is at least 70 beats per minute. 
Procoralan je zdravilo za srce, ki se uporablja za zdravljenje simptomov kronične stabilne angine pektoris (bolečin v prsih, čeljusti in hrbtu zaradi telesnega napora) pri odraslih z boleznijo koronarnih arterij (boleznijo srca, ki jo povzroča zapora v krvnih žilah, ki oskrbujejo srčno mišico).Zdravilo se uporablja pri bolnikih z normalnim srčnim ritmom, katerih srčni utrip je vsaj 70 udarcev na minuto.
The active substance in Procoralan, ivabradine, works by blocking the ‘If currents' in the sinus node, the ‘pacemaker' for the heart that controls the heart's contractions and regulates the heart rate. 
Zdravilna učinkovina v zdravilu Procoralan, ivabradin, deluje tako, da zavira „tokove If“ v sinusnem vozlu, tj. spodbujevalniku srca, ki nadzoruje krčenje srca in uravnava srčni utrip.
How is Procoralan used? 
Kako se zdravilo Procoralan uporablja?
It also concluded that Procoralan was effective in long-term heart failure with an acceptable safety profile. 
Prav tako je zaključila, da je zdravilo Procoralan učinkovito pri zdravljenju kroničnega srčnega popuščanja in ima sprejemljiv varnostni profil.
How does Procoralan work? 
Kako zdravilo Procoralan deluje?
For the full list of all side effects reported with Procoralan, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Procoralan, glejte navodilo za uporabo.
For the full list of restrictions with Procoralan, see the package leaflet. 
Za celoten seznam omejitev pri uporabi zdravila Procoralan glejte navodilo za uporabo.
For the treatment of angina, Procoralan was originally authorised for patients whose heart rate is at least 60 beats per minute. 
Zdravilo Procoralan je bilo za zdravljenje angine pektoris prvotno odobreno za uporabo pri bolnikih s srčnim utripom vsaj 60 udarcev na minuto, vendar je bila pozneje njegova uporaba omejena zgolj na bolnike s srčnim utripom vsaj 70 udarcev na minuto1.
Treatment must be stopped if the heart rate is persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue despite dose reduction. 
Pri bolnikih, starejših od 75 let, se lahko uporabi manjši začetni odmerek 2,5 mg dvakrat na dan. Zdravljenje je treba prekiniti, če srčni utrip stalno pada pod 50 udarcev na minuto ali če se nadaljujejo simptomi bradikardije (počasnega srčnega utripa).
What measures are being taken to ensure the safe and effective use of Zubsolv? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zubsolv?
The tablets are taken once a day by placing them under the tongue and allowing them to dissolve for up to 10 minutes. 
Bolniki tablete jemljejo enkrat na dan tako, da jih položijo pod jezik in pustijo do 10 minut, da se raztopijo.
The full EPAR for Zubsolv can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zubsolv je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Once the patient has been stabilised, the maintenance dose may be reduced gradually if the patients agrees, and eventually treatment may be stopped. 
Ko je bolnikovo stanje stabilno, se lahko vzdrževalni odmerek postopoma zmanjša, če se bolnik strinja, in zdravljenje navsezadnje zaključi.
Zubsolv is available as tablets of various strengths (0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg, 11.4 mg/2.9 mg). 
Zdravilo Zubsolv je na voljo v obliki tablet različnih jakosti (0,7 mg/0,18 mg, 1,4 mg/0,36 mg, 2,9 mg/0,71 mg, 5,7 mg/1,4 mg, 8,6 mg/2,1 mg, 11,4 mg/2,9 mg).
What is Zubsolv and what is it used for? 
Kaj je zdravilo Zubsolv in za kaj se uporablja?
Sublingual tablets containing buprenorphine alone have been available in the EU since the mid-1990s for the treatment of opioid addiction. 
Podjezične tablete, ki vsebujejo zgolj buprenorfin, so za zdravljenje zasvojenosti z opioidi v EU na voljo od sredine devetdesetih let prejšnjega stoletja.
It is not intended to provide practical advice on how to use Zubsolv. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The study also showed that Zubsolv tablets dissolved faster and had a better taste than the reference medicine. 
Študija je pokazala tudi, da se tablete zdravila Zubsolv hitro raztopijo in imajo boljši okus kot referenčno zdravilo.
This is a summary of the European public assessment report (EPAR) for Zubsolv. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zubsolv.
What are the risks associated with Zubsolv? 
Kakšna tveganja so povezana z zdravilom Zubsolv?
Zubsolv is a medicine used in adults and adolescents aged over 15 years to treat dependence on opioid (narcotic) drugs such as heroin or morphine. 
Zdravilo Zubsolv je zdravilo, ki se uporablja pri odraslih in mladostnikih, starejših od 15 let, za zdravljenje odvisnosti od opioidov (narkotikov), kot sta heroin in morfin.
What benefits of Zubsolv have been shown in studies? 
Kakšne koristi je zdravilo Zubsolv izkazalo v študijah?
Zubsolv is a ‘hybrid medicine'. 
Zdravilo Zubsolv je „hibridno zdravilo“.
Zubsolv is used in individuals who are also receiving medical, social and psychological support and who have agreed to be treated for their addiction. 
Zdravilo Zubsolv se uporablja pri osebah, ki prejemajo tudi zdravstveno, socialno in psihološko podporo ter so privolili v zdravljenje zasvojenosti.
A study involving 125 healthy volunteers showed that some strengths of the Zubsolv tablets produced a lower level of the active substances in the body than the reference product and therefore the two medicines cannot be used interchangeably. 
Študija, ki je vključevala 125 zdravih prostovoljcev, je pokazala, da so nekatere jakosti tablet zdravila Zubsolv privedle do nižje ravni zdravilnih učinkovin v telesu kot referenčno zdravilo, zato teh dveh zdravil ni možno uporabljati izmenično.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zubsolv have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zubsolv upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
It must also not be used with the medicines naltrexone and nalmefene, other opioid antagonists used for the treatment of alcohol or opioid dependence. 
Prav tako se ne sme uporabljati skupaj z naltreksonom in nalmefenom, drugima opioidnima antagonistoma, ki se uporabljata za zdravljenje odvisnosti od alkohola in opioidov.
As for Suboxone, the European Medicines Agency decided that Zubsolv's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Kot za zdravilo Suboxone je Evropska agencija za zdravila zaključila, da so koristi zdravila Zubsolv večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
The company provided data from studies with the reference medicine Suboxone and from the published literature showing the benefits of buprenorphine and naloxone in the treatment of opioid dependence. 
Družba je predložila podatke iz študij z referenčnim zdravilom Suboxone in iz objavljene literature, ki kažejo koristi buprenorfina in naloksona pri zdravljenju opioidne odvisnosti.
This means that it is similar to a ‘reference medicine' containing the same active substances, but Zubsolv contains these at different strengths. 
To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enaki zdravilni učinkovini, vendar sta v zdravilu Zubsolv prisotni v večji jakosti.
Other information about Zubsolv 
Druge informacije o zdravilu Zubsolv
For more information about treatment with Zubsolv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zubsolv preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Zubsolv contains two active substances: buprenorphine, a partial opioid agonist (it acts like an opioid drug but less powerfully), and naloxone, an opioid antagonist (it counteracts the effects of opioid drugs). 
Zdravilo Zubsolv vsebuje dve zdravilni učinkovini: buprenorfin, ki je delni opioidni agonist (deluje kot opioidno zdravilo, vendar ni tako močno), in nalokson, ki je opioidni antagonist (izniči učinke opioidnih zdravil).
For practical information about using Zubsolv, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Zubsolv naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Zubsolv must not be used in patients with severe respiratory insufficiency (inability to breathe properly), severe liver problems, acute alcoholism (excessive alcohol consumption) or delirium tremens (a condition caused by alcohol withdrawal). 
Zdravilo Zubsolv se ne sme uporabljati pri bolnikih s hudo respiratorno insuficienco (oslabljenim dihanjem), hudimi težavami z jetri, akutnim alkoholizmom (čezmernim uživanjem alkohola) ali stanjem delirium tremens (stanjem zaradi odtegnitve od alkohola).
The reference medicine for Zubsolv is Suboxone. 
Referenčno zdravilo za zdravilo Zubsolv je zdravilo Suboxone.
The most common side effects with Zubsolv (which may affect more than 1 in 10 people) are constipation and symptoms of drug withdrawal such as insomnia (difficulty sleeping), headache, nausea (feeling sick), hyperhidrosis (excessive sweating) and pain. 
Najpogostejši neželeni učinki zdravila Zubsolv (ki se lahko pojavijo pri več kot 1 osebi od 10) so zaprtost in odtegnitveni simptomi, kot so nespečnost, glavobol, navzeja (siljenje na bruhanje), hiperhidroza (pretirano znojenje) in bolečine.
Serious side effects include seizures (fits), vomiting, diarrhoea and abnormal results of blood tests for liver function. 
Resni neželeni učinki obsegajo epileptične napade (krče), bruhanje, drisko in nenormalne rezultate krvnih preiskav za delovanje jeter.
Why is Zubsolv approved? 
Zakaj je bilo zdravilo Zubsolv odobreno?
The addition of naloxone helps prevent the misuse of the medicine. 
Z dodajanjem naloksona se prepreči možnost zlorabe tega zdravila.
Because Zubsolv can be misused or cause addiction, it can only be obtained by ‘special' prescription and must be used under the supervision of a doctor who has experience in the management of opioid addiction. 
Bolniki lahko zdravilo Zubsolv zlorabijo, zdravilo pa povzroči zasvojenost, zato se predpisuje in izdaja samo na posebni recept ter ga je treba uporabljati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem odvisnosti od opioidov.
Combining buprenorphine and naloxone is an established strategy for managing opioid dependence which prevents misuse of the medicine. 
Kombinacija buprenorfina in naloksona je uveljavljena strategija za obravnavo odvisnosti od opioidov, ki preprečuje zlorabo zdravila.
However, buprenorphine tablets have been misused by drug addicts who dissolve the tablets and inject themselves with the resulting solution. 
Vendar pa so jih odvisniki od drog zlorabljali tako, da so jih raztopili in si dobljeno raztopino vbrizgali.
Since Zubsolv does not produce the same amounts of buprenorphine and naloxone in the blood as the reference medicine, the medicines cannot be used interchangeably. 
Ker so ravni buprenorfina in naloksona v krvi po uporabi zdravila Zubsolv nižje kot po uporabi referenčnega zdravila, teh dveh zdravil ni možno uporabljati izmenično.
On the first day of treatment, the recommended daily dose is one or two tablets of Zubsolv 1.4 mg/0.36 mg or 2.9 mg/0.71 mg. During the next days, the doctor may increase the dose depending on the patient's response, but the daily dose should not be higher than 17.2 mg buprenorphine. 
Priporočeni dnevni odmerek na prvi dan zdravljenja je ena ali dve tableti zdravila Zubsolv 1,4 mg/0,36 mg ali 2,9 mg/0,71 mg.
For the full list of side effects reported with Zubsolv, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zubsolv, glejte navodilo za uporabo.
This is because, when injected, naloxone counteracts the effects of opioids, causing the patient to experience acute withdrawal symptoms. 
Nalokson namreč učinkuje tako, da v primeru vbrizgavanja izniči delovanje opioidov in pri bolniku sproži akutne odtegnitvene simptome.
It contains the active substances buprenorphine and naloxone. 
Vsebuje zdravilni učinkovini buprenorfin in nalokson.
How is Zubsolv used? 
Kako se zdravilo Zubsolv uporablja?
How does Zubsolv work? 
Kako zdravilo Zubsolv deluje?
90 capsules blister (PVC/Aclar/alu) 
90 kapsul peroralna uporaba pretisni omot (PVC/Aclar/alu)
Annex A_en 
Annex A_sl
MA (EU) Number 
Št. (EU) dovoljenja za promet
bene-Arzneimittel GmbH 
90 (9x10) kapsul peroralna uporaba plastenka (HDPE)) 300 (3x100) kapsul bene-Arzneimittel GmbH
MA (EU) number 
Številka (EU)
(Invented) name 
(Izmišljeno)
17 February 2011 EMA/121971/2011 EMEA/H/C/002091 
17. februar 2011 EMA/121971/2011 EMEA/H/C/002091
The application was withdrawn before ‘day 120'. 
Vlogo so umaknili pred 120. dnevom.
The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'. 
Dopis, s katerim družba agencijo obvešča o umiku vloge, je na voljo pod zavihkom „All documents“ (Vsi dokumenti).
The company provided data from the published literature on topotecan. 
Družba je predložila podatke iz objavljene literature o topotekanu.
As the CHMP was evaluating the initial documentation provided by the company, it had not yet made any recommendations. 
Ker je CHMP takrat še ocenjeval začetno dokumentacijo, ki jo je predložila družba, še ni podal nobenih priporočil.
This means that the CHMP was still evaluating the initial documentation provided by the company. 
To pomeni, da je CHMP še vedno ocenjeval začetno dokumentacijo, ki jo je predložila družba.
• metastatic cancer of the ovary (when the cancer has spread to other parts of the body) after at least one other treatment has failed; 
• metastatskim rakom jajčnikov (kadar se je rak razširil tudi na druge dele telesa) po neuspešnem zdravljenju z vsaj enim drugim zdravilom;
On 3 January 2011, Sun Pharmaceutical Industries Europe B.V. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Topotecan SUN for the treatment metastatic cancer of the ovary, small cell lung cancer and cervical cancer. 
je dne 3. januarja 2011 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za dovoljenje za promet z zdravilom Topotecan SUN, namenjenim za zdravljenje metastatskega raka jajčnikov, drobnoceličnega pljučnega raka in raka materničnega vratu.
It was also to be used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer had come back after radiotherapy, or when the disease was at an advanced stage (stage IVB: the cancer has spread beyond the cervix). 
Zdravilo naj bi se uporabljalo tudi skupaj s cisplatinom (druga vrsta zdravila proti raku) za zdravljenje žensk z rakom materničnega vratu, če se je rak ponovno pojavil po že končanem zdravljenju z obsevanjem ali če je bila bolezen v napredovalem stadiju (stadij IVB: rak se je razširil prek meja materničnega vratu).
This means that Topotecan SUN was intended to be similar to a ‘reference medicine' already authorised in the European Union called Hycamtin. 
To pomeni, da naj bi bilo zdravilo Topotecan SUN podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji, in sicer zdravilu Hycamtin.
• small cell lung cancer, when the cancer has relapsed (come back). 
• drobnoceličnim pljučnim rakom, kadar se je rak ponovno pojavil (relaps).
Topotecan SUN was to be used on its own to treat patients with: 
Zdravilo Topotecan SUN naj bi se uporabljalo samostojno za zdravljenje bolnikov z:
Topotecan SUN was developed as a ‘generic medicine'. 
Zdravilo Topotecan SUN je bilo razvito kot „generično zdravilo“.
Withdrawal of the marketing authorisation application for Topotecan SUN (topotecan) 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Topotecan SUN (topotekan)
Topotecan SUN also affects non-cancer cells, which causes side effects. 
Zdravilo Topotecan SUN vpliva tudi na nerakaste celice, kar povzroča neželene učinke.
What were the reasons given by the company for withdrawing the application? 
Kakšni so bili razlogi družbe za umik vloge
This prevents the cancer cells from dividing and they eventually die. 
To rakastim celicam preprečuje deljenje in sčasoma odmrejo.
When the enzyme is blocked, the DNA strands break. 
Z zaviranjem delovanja encima začnejo verige DNK razpadati.
It contains the active substance topotecan. 
Vsebuje zdravilno učinkovino topotekan.
The active substance in Topotecan SUN, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'. 
Zdravilna učinkovina v zdravilu Topotecan SUN, topotekan, je zdravilo proti raku, ki sodi v skupino „zaviralcev topoizomeraze“.
It blocks an enzyme called topoisomerase I, which is involved in the division of DNA. 
Zdravilo zavira encim, imenovan topoizomeraza I, ki sodeluje v procesu deljenja DNK.
What is Topotecan SUN? 
Kaj je zdravilo Topotecan SUN?
Topotecan SUN is a powder to be made up into a solution for infusion (drip into a vein). 
Zdravilo Topotecan SUN je prašek, ki se pripravi v raztopino za infundiranje (kapalna infuzija v veno).
How is Topotecan SUN expected to work? 
Kako naj bi zdravilo Topotecan SUN delovalo?
No additional studies were needed as Topotecan SUN is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin. 
Ker je zdravilo Topotecan generično zdravilo, ki se daje z infuzijo in vsebuje enako zdravilno učinkovino kot referenčno zdravilo Hycamtin, niso bile potrebne nobene dodatne študije.
What was Topotecan SUN expected to be used for? 
Za kaj naj bi se zdravilo Topotecan SUN uporabljalo?
There are no specific risks for the user. 
Za uporabnika ni posebnih tveganj.
Milk can be taken immediately. 
Mleko se lahko uporabi takoj.
This summary was last updated on 27 January 2011. 
Ta povzetek je bil nazadnje posodobljen dne 27/01/2011.
This will help to protect against the disease. 
To pomaga pri obrambi pred boleznijo.
This slight swelling lasts for less than a day in most cases. 
Rahla oteklina traja v večini primerov manj kot en dan.
This increase can sometimes be higher (up to 1.6º C in adult cows and up to 2.2º C in calves). 
To povišanje je v nekaterih primerih lahko višje (do 1,6°C pri odraslih kravah in do 2,2°C pri teletih).
The rise in temperature is temporary and spontaneously resolved within two days without treatment. 
Povišanje telesne temperature je začasno in brez zdravljenja spontano izzveni v dveh dneh.
The virus is alive, but it has also been attenuated (weakened) to further lower its ability to cause infection. 
Virus je živ, vendar oslabljen, zaradi česar je še nadalje zmanjšana možnost, da povzroči okužbo.
The efficacy of the vaccine was studied in three laboratory studies including one study looking at the duration of immunity. 
Učinkovitost cepiva je bila raziskana v treh laboratorijskih študijah, vključno z eno, ki je raziskala trajanje imunosti.
Afterward a single ‘booster' can be given every six months to maintain the vaccine's effect. 
Vsakih šest mesecev je treba nato dati spodbujevalni odmerek za vzdrževanje učinka cepiva.
The first injection can be given to calves from three months of age. 
Prvo injekcijo lahko prejmejo teleta od starosti treh mesecev dalje.
What is the time to allow before milk can be taken from the animal for human consumption? 
Koliko časa je treba počakati, preden se mleko živali uporabi za prehrano ljudi?
This vaccine is a marker vaccine and can enable a differential testing of vaccinated and naturally infected cattle, which is a useful tool in eradication campaigns. 
To cepivo je marker cepivo, ki lahko omogoči razlikovalno testiranje cepljenega in naravno okuženega goveda, kar je pomembno orodje pri ukrepih zatiranja bolezni.
In the future, if the animals are exposed to the IBR virus, the immune system will be able to respond more quickly. 
Ob ponovni izpostavitvi virusu IBR v prihodnosti se bo imunski sistem tako hitreje odzval.
The vaccine is given to animals as two injections, three weeks apart, into the neck muscles. 
Cepivo se daje živalim v obliki dveh injekcij v vratne mišice v razmiku treh tednov.
Studies also looked at the safety of the vaccine in pregnant animals. 
V študijah so raziskovali tudi varnost cepiva pri brejih živalih.
After vaccination, animals may show a slight increase in body temperature up to 1° C, in the four days following vaccination. 
V štirih dneh po cepljenju se lahko pri živalih telesna temperatura poviša za največ 1°C .